24 September 2020: Clinical Research
A Retrospective Study from 2 Centers in China on the Effects of Continued Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Patients with Hypertension and COVID-19
Zhongchao Wang 1ABCDEFG* , Dewei Zhang 2BC* , Shengming Wang 3BC* , Yanhua Jin 2BC* , Jianbo Huan 4BC* , Yue Wu 5CDF* , Cheng Xia 2CD , Zhe Li 6B , Xingshun Qi 7CF , Duanzhen Zhang 8DF , Xiumin Han 8DF , Xianyang Zhu 8DEF , Ying Qu 9ABCDEFG* , Qiguang Wang 8ACDEFG*DOI: 10.12659/MSM.926651
Med Sci Monit 2020; 26:e926651
Table 5 Clinical outcomes and adverse events of COVID-19 patients complicated with hypertension after propensity score matching.
| Parameters | Overall (n=124) | ACEIs/ARBs (n=62) | Non-ACEIs/ARBs (n=62) | P value |
|---|---|---|---|---|
| Clinical outcomes | ||||
| Death during hospitalization, n (%) | 8 (6.45) | 4 (6.45) | 4 (6.45) | 1.000 |
| 7-categorical ordinal scale at discharge | ||||
| ≤2, n (%) | 107 (86.29) | 52 (83.87) | 55 (88.71) | 0.433 |
| >2, n (%) | 17 (13.71) | 10 (16.13) | 7 (11.29) | 0.433 |
| Days of hospital stay, median (IQR) | 16.50 (13.00–21.00) | 17.00 (13.00–22.00) | 16.00 (13.00–20.00) | 0.768 |
| Number of ICU stay cases during hospitalization, n (%) | 14 (11.29) | 8 (12.90) | 6 (9.68) | 0.570 |
| Ratio of ICU days during hospitalization (%), median (IQR) | 73.86 (51.43–100.00) | 72.08 (53.64–97.22) | 87.50 (42.62–100.00) | 0.755 |
| Number of cases with symptom relief, n (%) | 108 (87.10) | 54 (87.10) | 54 (87.10) | 1.000 |
| Ratio of days from treatment initiation to symptom relief (%), median (IQR) | 36.75 (20.21–59.13) | 35.83 (20.63–78.33) | 40.06 (19.84–55.73) | 0.621 |
| Number of cases with SARS-CoV-2 nuclei acid testing turning negative, n (%) | 120 (96.77) | 60 (96.77) | 60 (96.77) | 1.000 |
| Ratio of days from treatment initiation to first negative SARS-CoV-2 nuclei acid testing (%), median (IQR) | 28.99 (15.10–46.54) | 29.71 (16.17–45.98) | 27.62 (14.29–47.48) | 0.937 |
| Number of cases with CT-shown absorption of pulmonary infection, n (%) | 114 (91.94) | 58 (93.55) | 56 (90.32) | 0.742 |
| Ratio of days from treatment initiation to definite CT-shown absorption of pulmonary infection (%), median (IQR) | 68.47 (52.57–81.95) | 66.67 (44.46–80.31) | 69.78 (58.33–83.99) | 0.211 |
| Ratio of days of BP above normal range (%), median (IQR) | 43.30 (21.63–71.22) | 42.33 (26.34–73.30) | 44.16 (15.95–67.65) | 0.577 |
| BP values above normal range | ||||
| mSBP (mmHg), median (IQR) | 6.70 (2.00–11.67) | 7.00 (3.00–11.54) | 5.93 (0.75–11.75) | 0.414 |
| mDBP (mmHg), median (IQR) | 2.00 (0.00–4.97) | 3.13 (0.00–5.55) | 1.00 (0.00–4.38) | 0.425 |
| eSBP (mmHg), median (IQR) | 7.66 (3.50–12.32) | 8.00 (3.66–12.75) | 7.07 (3.28–11.99) | 0.419 |
| eDBP (mmHg), median (IQR) | 2.50 (0.00–6.46) | 2.75 (0.00–6.63) | 2.42 (0.00–6.38) | 0.997 |
| Adverse events, n (%) | 6 (4.84) | 3 (4.84) | 3 (4.84) | 1.000 |
| ACEIs – angiotensin-converting enzyme inhibitors; ARBs – angiotensin II receptor blockers; IQR – interquartile range; SARS-CoV-2 – severe acute respiratory syndrome coronavirus 2; CCBs – calcium channel blockers; ICU – Intensive Care Unit; m/eSBP – morning/evening systolic pressure; m/eDBP – morning/evening diastolic pressure. | ||||